The small molecule ML385, identified via high throughput screening, interacts with the Nrf2 DNA-binding domain to prevent binding to AREs and was found to enhance cytotoxicity of chemotherapeutic agents in NSCLC cells including an Nrf2-mutant LSCC cell line [213]. Here, NFE2L2 is linked to non-small cell lung carcinoma.